Créer une activité

Coronavirus-2

The company accelerated its push to study remdesivir after Chinese scientists said Jan. 9 that they had identified the source of the outbreak as a coronavirus, a family of diseases common in animals that can cause severe respiratory illness when transmitted to humans. Gilead invented remdesivir several years ago and first developed it to treat Ebola, a virus that has ravaged parts of eastern and central Africa. The drug was less effective than rival drugs in a study of Ebola patients in Congo last year. Yet Gilead had reason to think remdesivir might work in coronaviruses. Company researchers working with academic scientists found that remdesivir was effective in treating mice infected with another coronavirus known as Middle East respiratory syndrome, or MERS. The work was partially funded with $3.8 million in grants from the National Institutes of Health. The mice studies were far from definitive but suggested the drug had promise against the new coronavirus. The data were published in the journal Nature Communications on Jan. 10. “The attention level went up dramatically when we found out it was a coronavirus, and that was the turning point,” Dr. Parsey says. “That’s when we got mobilized and formed a team across the company to see what we could do here.” Gilead was soon exchanging information about the virus with officials from the Chinese Center for Disease Control and Prevention, the World Health Organization and the U.S. Centers for Disease Control and Prevention. They discussed how to determine if remdesivir might be effective at treating the outbreak. By Jan. 20, Gilead was in talks with Beijing pulmonologist Cao Bin, a prominent researcher deployed to Wuhan to help lead the medical care of patients. With input from the U.S. Food and Drug Administration and the WHO, Gilead worked with Dr. Cao’s team to design the studies, says Gilead’s Diana Brainard, senior vice president for HIV and emerging viral infections. The trials are being conducted at several hospitals in Wuhan, according to Chinese news reports. Last week, Gilead shipped the last batch of remdesivir needed to supply the two studies, the first in patients with mild-to-moderate disease and the second in patients with severe disease. The studies are expected to be completed in early April. “We’re all tracking the number of infections and deaths, and we really want to help,” says Dr. Brainard. The company’s “coronavirus response team” now numbers about 100 employees across the company and includes executives from all major departments. Gilead employees in the U.S., along with many of the 400 employees it has in Beijing and Shanghai, have worked hundreds of extra hours since the mobilization began, juggling 3 a.m. conference calls, late-night text messages and 7 a.m. office meetings to keep up with colleagues in different time zones, Dr. Brainard says.
biochemistry epidemiology Âge recommandé: 21 ans
0 fois fait

Créé par

Martin Smith
Martin Smith
United Kingdom

Top 10 résultats

Il n'y a toujours pas de résultats pour cette activité. Soyez le premier à apparaître dans le classement! Connectez-vous pour vous identifier.
Créez votre propre activité gratuite à partir de notre créateur d'activité
Affrontez vos amis pour voir qui obtient le meilleur score dans cette activité

0 Commentaires

Connectez-vous pour écrire un commentaire.
  1. temps
    but
  1. temps
    but
temps
but
temps
but